CARLA Biotherapeutics
Summary
CARLA Biotherapeutics is building a portfolio of cell immunotherapies aimed at diseases with high unmet medical need. The company says its first patented CAR-T program has orphan drug status and comes from the UMR RIGHT lab in Besançon. That program targets CD123-positive leukemias. CARLA is also developing a second CAR-T program for solid tumors using a novel approach.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected